In Brief: FDA's Anesthetic & Life Support Drugs Advisory Committee
Executive Summary
FDA's Anesthetic & Life Support Drugs Advisory Committee: Will meet April 29 to discuss Glaxo Wellcome's remifentanil (NDA 20-630) for use as a general anesthetic. On April 30, the committee will review Abbott's Ultane Phase IV and post-marketing data. The meeting begins at 8:30 a.m. at the Holiday Inn in Bethesda, Md...